Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07315503) titled 'An Open-label Study of GC012F in Rheumatoid Arthritis' on Dec. 18, 2025.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Condition:
Rheumatoid Arthritis
Intervention:
Drug: LD and GC012F CAR-T Cell Injection
Recruitment Status: Not recruiting
Phase: Early Phase 1
Date of First Enrollment: January 15, 2026
Target Sample Size: 9
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/study/NCT073...